{'52WeekChange': 1.9078948,
 'SandP52WeekChange': None,
 'address1': '2223 Avenida De La Playa',
 'address2': 'Suite 105',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.5,
 'askSize': 1400,
 'averageDailyVolume10Day': 4099575,
 'averageVolume': 2456844,
 'averageVolume10days': 4099575,
 'beta': None,
 'beta3Year': None,
 'bid': 13.25,
 'bidSize': 1000,
 'bookValue': 2.055,
 'category': None,
 'circulatingSupply': None,
 'city': 'La Jolla',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.5,
 'dayLow': 12.41,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.101,
 'enterpriseToRevenue': None,
 'enterpriseValue': 197444576,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.3945713,
 'fiftyTwoWeekHigh': 27.05,
 'fiftyTwoWeekLow': 2.2,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 6589753,
 'forwardEps': -1.69,
 'forwardPE': -7.8757396,
 'fromCurrency': None,
 'fullTimeEmployees': 22,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.63329,
 'heldPercentInstitutions': 0.26007,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/equilliumbio.com',
 'longBusinessSummary': 'Equillium, Inc., a clinical-stage biotechnology '
                        'company, develops products for autoimmune and '
                        'inflammatory, or immuno-inflammatory disorders with '
                        'unmet medical need. Its primary product candidate is '
                        'itolizumab, a clinical-stage monoclonal antibody that '
                        'targets the novel immune checkpoint receptor CD6, '
                        'which is in Phase 1b/2 clinical trials for the '
                        'treatment of acute graft-versus-host disease; and '
                        'Phase 1 clinical trial for the treatment of asthma '
                        'and lupus nephritis. The company was formerly known '
                        'as Attenuate Biopharmaceuticals, Inc. and changed its '
                        'name to Equillium, Inc. in May 2017. Equillium, Inc. '
                        'was founded in 2017 and is headquartered in La Jolla, '
                        'California.',
 'longName': 'Equillium, Inc.',
 'market': 'us_market',
 'marketCap': 235374048,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_575585027',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -27487000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.7,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 412 5302',
 'previousClose': 13.26,
 'priceHint': 2,
 'priceToBook': 6.476886,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.5,
 'regularMarketDayLow': 12.41,
 'regularMarketOpen': 12.7,
 'regularMarketPreviousClose': 13.26,
 'regularMarketPrice': 12.7,
 'regularMarketVolume': 521364,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17684000,
 'sharesPercentSharesOut': 0.00059999997,
 'sharesShort': 11308,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 75703,
 'shortName': 'Equillium, Inc.',
 'shortPercentOfFloat': 0.0027,
 'shortRatio': 0.25,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'EQ',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.577,
 'twoHundredDayAverage': 4.362878,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2dcbad74-77fd-3056-9e8b-8198f173bd47',
 'volume': 521364,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://equilliumbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92037'}